Pay in 4 interest-free payments of $6.74 Learn more
Ships within 48 hours · Estimated delivery Aug 22 - Aug 27
Each batch includes a Certificate of Analysis
The NDA is based on results from REDEFINE 1, a 68-week, phase 3, randomised, double-blind, placebo-and active-controlled trial that evaluated the efficacy and safety of once-weekly, CagriSema compared to semaglutide 2.4 mg alone, cagrilintide 2.4 mg alone, or placebo, all as an adjunct to lifestyle intervention in 3,417 adults with obesity (BMI 30 kg/m2) or overweight (BMI 27 kg/m2) with one or more obesity-related complications and without diabetes, and REDEFINE 2, a double-blind, randomised, placebo-controlled, 68-week, phase 3 trial that evaluated the efficacy and safety of once-weekly CagriSema versus placebo, as an adjunct to lifestyle intervention in 1,206 adults with type 2 diabetes and either obesity (BMI 30 kg/m2) or overweight (BMI 27 kg/m2)
Patients with FMD were older (adjusted odds ratio [aOR] per 10 years = 1.19
This study addresses this gap by analysing how China has used the advantage of party-state authority to navigate market dynamics and crises in the real estate market, contributing to the global discourse on planetary urbanisation and land financialisation
US$ 20.60
US$ 20.47
US$ 22.03
US$ 26.70
US$ 24.44
US$ 23.59
